Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 13, 2026 - 02:54

Damora Therapeutics has released its financial results for the first quarter of 2026, alongside a series of corporate updates focused on advancing its pipeline of antibody therapies. The company is preparing to present new preclinical data for its lead candidate, DMR-001, at the upcoming 2026 European Hematology Association Congress. The data is expected to highlight what the company describes as potentially best-in-class potency, extended half-life, and strong anti-mutCALR activity.

DMR-001 is an Fc-null antibody designed to target the mutant calreticulin protein, a driver in certain myeloproliferative neoplasms. The company also provided updates on DMR-002, an Fc-enhanced version of the same antibody. Damora remains on track to submit its first regulatory filings for DMR-001 in mid-2026, with a submission for DMR-002 expected in the second half of the year. These filings are intended to enable the start of clinical development for both programs.

In addition to pipeline progress, Damora announced the appointment of a new CEO and several key leadership team members. The company stated that these additions are part of a broader effort to accelerate its vision of redefining care for patients with blood cancers and related disorders. The financial report did not include any forward-looking revenue figures, as the company remains in the preclinical and early regulatory stages.